Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review

The detection of premenopausal women at high risk of breast cancer is key to chemoprevention. Therapy with selective estrogen receptor modulators (SERMs) induces a significant antiproliferative effect in estrogen receptor (ER) positive breast cancer. This review was designed according the guidelines...

Full description

Saved in:
Bibliographic Details
Published in:Translational cancer research 2020-07, Vol.9 (7), p.4444-4456
Main Authors: Oceguera-Basurto, Paola, Topete, Antonio, Oceguera-Villanueva, Antonio, Rivas-Carrillo, Jorge, Paz-Davalos, Marco, Quintero-Ramos, Antonio, Del Toro-Arreola, Alicia, Daneri-Navarro, Adrián
Format: Article
Language:English
Subjects:
Review
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c384t-bedbc989aaedc3fa1e6b0b8c36c625cca35de11a335b5ac35e01cdcfd0ff68ba3
cites
container_end_page 4456
container_issue 7
container_start_page 4444
container_title Translational cancer research
container_volume 9
creator Oceguera-Basurto, Paola
Topete, Antonio
Oceguera-Villanueva, Antonio
Rivas-Carrillo, Jorge
Paz-Davalos, Marco
Quintero-Ramos, Antonio
Del Toro-Arreola, Alicia
Daneri-Navarro, Adrián
description The detection of premenopausal women at high risk of breast cancer is key to chemoprevention. Therapy with selective estrogen receptor modulators (SERMs) induces a significant antiproliferative effect in estrogen receptor (ER) positive breast cancer. This review was designed according the guidelines of the 2009 PRISMA statement. Searching different databases, including PubMed, MedlinePlus, PLoS One, Cochrane Breast Cancer Specialized Register, Clinical Trials.gov and American Society of Clinical Oncology. From 168 records screened, 15 full text articles were assessed for eligibility and only 7 studies met the inclusion criteria. Three of the studies included analyzed changes in Ki-67 expression, revealing weaker expression after treatment with acolbifene and raloxifene (P
doi_str_mv 10.21037/tcr-19-1956
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8797886</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2626005817</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-bedbc989aaedc3fa1e6b0b8c36c625cca35de11a335b5ac35e01cdcfd0ff68ba3</originalsourceid><addsrcrecordid>eNpVkc1LxDAQxYMorqg3z5KjB6tJs01TD4KIXyB4UMFbmE6na6VtatKu-N-b9QuFgXlhfrwZ8hjbk-IolULlxyP6RBaxMr3GttI0am2EWv_UJtG5fpqx3RBehBCplGYu9CabqUzK3Ihii73cU0s4NkviFEbvFtRzT0jD6DzvXDW1EFXgTc_HZ-KDpyX1Y-N67mpeeoIwcoQeya-QOO6odwNMAVr-5uLjhEM0XDb0tsM2amgD7X73bfZ4efFwfp3c3l3dnJ_dJqjMfExKqkosTAFAFaoaJOlSlAaVRp1miKCyiqQEpbIyA1QZCYkV1pWoa21KUNvs9Mt3mMouesR7PbR28E0H_t06aOz_Sd8824VbWpMXuTE6Ghx8G3j3OsVvsV0TkNoWenJTsKlOtRCZkXlED79Q9C4ET_XvGinsZ0I2JmRlYVcJRXz_72m_8E8e6gPRhZGe</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2626005817</pqid></control><display><type>article</type><title>Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review</title><source>PubMed Central Free</source><creator>Oceguera-Basurto, Paola ; Topete, Antonio ; Oceguera-Villanueva, Antonio ; Rivas-Carrillo, Jorge ; Paz-Davalos, Marco ; Quintero-Ramos, Antonio ; Del Toro-Arreola, Alicia ; Daneri-Navarro, Adrián</creator><creatorcontrib>Oceguera-Basurto, Paola ; Topete, Antonio ; Oceguera-Villanueva, Antonio ; Rivas-Carrillo, Jorge ; Paz-Davalos, Marco ; Quintero-Ramos, Antonio ; Del Toro-Arreola, Alicia ; Daneri-Navarro, Adrián</creatorcontrib><description>The detection of premenopausal women at high risk of breast cancer is key to chemoprevention. Therapy with selective estrogen receptor modulators (SERMs) induces a significant antiproliferative effect in estrogen receptor (ER) positive breast cancer. This review was designed according the guidelines of the 2009 PRISMA statement. Searching different databases, including PubMed, MedlinePlus, PLoS One, Cochrane Breast Cancer Specialized Register, Clinical Trials.gov and American Society of Clinical Oncology. From 168 records screened, 15 full text articles were assessed for eligibility and only 7 studies met the inclusion criteria. Three of the studies included analyzed changes in Ki-67 expression, revealing weaker expression after treatment with acolbifene and raloxifene (P&lt;0.001). Three studies also analyzed the breast volume by magnetic resonance imagining (MRI) and demonstrate a significant difference after 1 year with raloxifene treatment (P=0.0017). Moreover, a 20% reduction in breast density was observed after a 2-year treatment with tamoxifen in premenopausal women. SERMs reduce the risk of developing breast cancer. The studies reviewed here demonstrate the modulation of Ki-67 expression and changes in breast density, suggesting an important preventive role for this group of drugs in prevention for premenopausal women at high risk of developing breast cancer.</description><identifier>ISSN: 2218-676X</identifier><identifier>EISSN: 2219-6803</identifier><identifier>DOI: 10.21037/tcr-19-1956</identifier><identifier>PMID: 35117809</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Review</subject><ispartof>Translational cancer research, 2020-07, Vol.9 (7), p.4444-4456</ispartof><rights>2020 Translational Cancer Research. All rights reserved.</rights><rights>2020 Translational Cancer Research. All rights reserved. 2020 Translational Cancer Research.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-bedbc989aaedc3fa1e6b0b8c36c625cca35de11a335b5ac35e01cdcfd0ff68ba3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797886/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797886/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35117809$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oceguera-Basurto, Paola</creatorcontrib><creatorcontrib>Topete, Antonio</creatorcontrib><creatorcontrib>Oceguera-Villanueva, Antonio</creatorcontrib><creatorcontrib>Rivas-Carrillo, Jorge</creatorcontrib><creatorcontrib>Paz-Davalos, Marco</creatorcontrib><creatorcontrib>Quintero-Ramos, Antonio</creatorcontrib><creatorcontrib>Del Toro-Arreola, Alicia</creatorcontrib><creatorcontrib>Daneri-Navarro, Adrián</creatorcontrib><title>Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review</title><title>Translational cancer research</title><addtitle>Transl Cancer Res</addtitle><description>The detection of premenopausal women at high risk of breast cancer is key to chemoprevention. Therapy with selective estrogen receptor modulators (SERMs) induces a significant antiproliferative effect in estrogen receptor (ER) positive breast cancer. This review was designed according the guidelines of the 2009 PRISMA statement. Searching different databases, including PubMed, MedlinePlus, PLoS One, Cochrane Breast Cancer Specialized Register, Clinical Trials.gov and American Society of Clinical Oncology. From 168 records screened, 15 full text articles were assessed for eligibility and only 7 studies met the inclusion criteria. Three of the studies included analyzed changes in Ki-67 expression, revealing weaker expression after treatment with acolbifene and raloxifene (P&lt;0.001). Three studies also analyzed the breast volume by magnetic resonance imagining (MRI) and demonstrate a significant difference after 1 year with raloxifene treatment (P=0.0017). Moreover, a 20% reduction in breast density was observed after a 2-year treatment with tamoxifen in premenopausal women. SERMs reduce the risk of developing breast cancer. The studies reviewed here demonstrate the modulation of Ki-67 expression and changes in breast density, suggesting an important preventive role for this group of drugs in prevention for premenopausal women at high risk of developing breast cancer.</description><subject>Review</subject><issn>2218-676X</issn><issn>2219-6803</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVkc1LxDAQxYMorqg3z5KjB6tJs01TD4KIXyB4UMFbmE6na6VtatKu-N-b9QuFgXlhfrwZ8hjbk-IolULlxyP6RBaxMr3GttI0am2EWv_UJtG5fpqx3RBehBCplGYu9CabqUzK3Ihii73cU0s4NkviFEbvFtRzT0jD6DzvXDW1EFXgTc_HZ-KDpyX1Y-N67mpeeoIwcoQeya-QOO6odwNMAVr-5uLjhEM0XDb0tsM2amgD7X73bfZ4efFwfp3c3l3dnJ_dJqjMfExKqkosTAFAFaoaJOlSlAaVRp1miKCyiqQEpbIyA1QZCYkV1pWoa21KUNvs9Mt3mMouesR7PbR28E0H_t06aOz_Sd8824VbWpMXuTE6Ghx8G3j3OsVvsV0TkNoWenJTsKlOtRCZkXlED79Q9C4ET_XvGinsZ0I2JmRlYVcJRXz_72m_8E8e6gPRhZGe</recordid><startdate>202007</startdate><enddate>202007</enddate><creator>Oceguera-Basurto, Paola</creator><creator>Topete, Antonio</creator><creator>Oceguera-Villanueva, Antonio</creator><creator>Rivas-Carrillo, Jorge</creator><creator>Paz-Davalos, Marco</creator><creator>Quintero-Ramos, Antonio</creator><creator>Del Toro-Arreola, Alicia</creator><creator>Daneri-Navarro, Adrián</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202007</creationdate><title>Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review</title><author>Oceguera-Basurto, Paola ; Topete, Antonio ; Oceguera-Villanueva, Antonio ; Rivas-Carrillo, Jorge ; Paz-Davalos, Marco ; Quintero-Ramos, Antonio ; Del Toro-Arreola, Alicia ; Daneri-Navarro, Adrián</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-bedbc989aaedc3fa1e6b0b8c36c625cca35de11a335b5ac35e01cdcfd0ff68ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Review</topic><toplevel>online_resources</toplevel><creatorcontrib>Oceguera-Basurto, Paola</creatorcontrib><creatorcontrib>Topete, Antonio</creatorcontrib><creatorcontrib>Oceguera-Villanueva, Antonio</creatorcontrib><creatorcontrib>Rivas-Carrillo, Jorge</creatorcontrib><creatorcontrib>Paz-Davalos, Marco</creatorcontrib><creatorcontrib>Quintero-Ramos, Antonio</creatorcontrib><creatorcontrib>Del Toro-Arreola, Alicia</creatorcontrib><creatorcontrib>Daneri-Navarro, Adrián</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Translational cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oceguera-Basurto, Paola</au><au>Topete, Antonio</au><au>Oceguera-Villanueva, Antonio</au><au>Rivas-Carrillo, Jorge</au><au>Paz-Davalos, Marco</au><au>Quintero-Ramos, Antonio</au><au>Del Toro-Arreola, Alicia</au><au>Daneri-Navarro, Adrián</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review</atitle><jtitle>Translational cancer research</jtitle><addtitle>Transl Cancer Res</addtitle><date>2020-07</date><risdate>2020</risdate><volume>9</volume><issue>7</issue><spage>4444</spage><epage>4456</epage><pages>4444-4456</pages><issn>2218-676X</issn><eissn>2219-6803</eissn><abstract>The detection of premenopausal women at high risk of breast cancer is key to chemoprevention. Therapy with selective estrogen receptor modulators (SERMs) induces a significant antiproliferative effect in estrogen receptor (ER) positive breast cancer. This review was designed according the guidelines of the 2009 PRISMA statement. Searching different databases, including PubMed, MedlinePlus, PLoS One, Cochrane Breast Cancer Specialized Register, Clinical Trials.gov and American Society of Clinical Oncology. From 168 records screened, 15 full text articles were assessed for eligibility and only 7 studies met the inclusion criteria. Three of the studies included analyzed changes in Ki-67 expression, revealing weaker expression after treatment with acolbifene and raloxifene (P&lt;0.001). Three studies also analyzed the breast volume by magnetic resonance imagining (MRI) and demonstrate a significant difference after 1 year with raloxifene treatment (P=0.0017). Moreover, a 20% reduction in breast density was observed after a 2-year treatment with tamoxifen in premenopausal women. SERMs reduce the risk of developing breast cancer. The studies reviewed here demonstrate the modulation of Ki-67 expression and changes in breast density, suggesting an important preventive role for this group of drugs in prevention for premenopausal women at high risk of developing breast cancer.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>35117809</pmid><doi>10.21037/tcr-19-1956</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2218-676X
ispartof Translational cancer research, 2020-07, Vol.9 (7), p.4444-4456
issn 2218-676X
2219-6803
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8797886
source PubMed Central Free
subjects Review
title Selective estrogen receptor modulators in the prevention of breast cancer in premenopausal women: a review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T12%3A44%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selective%20estrogen%20receptor%20modulators%20in%20the%20prevention%20of%20breast%20cancer%20in%20premenopausal%20women:%20a%20review&rft.jtitle=Translational%20cancer%20research&rft.au=Oceguera-Basurto,%20Paola&rft.date=2020-07&rft.volume=9&rft.issue=7&rft.spage=4444&rft.epage=4456&rft.pages=4444-4456&rft.issn=2218-676X&rft.eissn=2219-6803&rft_id=info:doi/10.21037/tcr-19-1956&rft_dat=%3Cproquest_pubme%3E2626005817%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c384t-bedbc989aaedc3fa1e6b0b8c36c625cca35de11a335b5ac35e01cdcfd0ff68ba3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2626005817&rft_id=info:pmid/35117809&rfr_iscdi=true